Spyre Therapeutics, Inc.SYRENASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank25
3Y CAGR+1.6%
5Y CAGR-33.7%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+1.6%/yr
vs -35.4%/yr prior
5Y CAGR
-33.7%/yr
Recent acceleration
Acceleration
+37.1pp
Accelerating
Percentile
P25
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 4.66% |
| 2024 | 14.59% |
| 2023 | 40.01% |
| 2022 | 4.44% |
| 2021 | 35.12% |
| 2020 | 36.31% |
| 2019 | 17.42% |
| 2018 | 25.49% |
| 2017 | 19.96% |
| 2016 | 41.10% |